Brief: Ab&B Bio Tech Enters Strategic Cooperation Agreement With Walvax Hong Kong
13/03/2026 11:00
March 13 (Reuters) - Ab&B Bio Tech Co Ltd JS 2627.HK: ENTERS STRATEGIC COOPERATION AGREEMENT WITH WALVAX HONG KONG LTD CORE PRODUCT FOR EXPANSION IS TRIVALENT SUBUNIT INFLUENZA VACCINE HUIERKANGXIN 3 Further company coverage: 2627.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ab&B Bio Tech JS
See all newsBrief: AB&B Bio Tech Co Says 2026 Interim Results Expected After Publication Of 2025 Annual Results
Brief: AB&B Bio Tech Co JS Says Li Runxiang Resigns As Executive Director And CFO
Brief: AB&B Bio Tech Announces Delay In Publication Of 2026 Interim Results And Report
Brief: Ab&B Bio Tech Enters Strategic Cooperation Agreement With Walvax Hong Kong
Ab&B Bio Tech hits record high on inclusion in Hang Seng Composite Index